Inhibition of Food Intake in Obese Subjects by Peptide YY 3–36
The DOI matches its Crossref record; 26 of the 27 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The gut hormone fragment peptide YY3-36 (PYY) reduces appetite and food intake when infused into subjects of normal weight. In common with the adipocyte hormone leptin, PYY reduces food intake by modulating appetite circuits in the hypothalamus. However, in obesity there is a marked resistance to the action of leptin, which greatly limits its therapeutic effectiveness. We investigated whether obese subjects were also resistant to the anorectic effects of PYY. METHODS: We compared the effects of PYY infusion on appetite and food intake in 12 obese and 12 lean subjects in a double-blind, placebo-controlled, crossover study. The plasma levels of PYY, ghrelin, leptin, and insulin were also determined. RESULTS: Caloric intake during a buffet lunch offered two hours after the infusion of PYY was decreased by 30 percent in the obese subjects (P<0.001) and 31 percent in the lean subjects (P<0.001). PYY infusion also caused a significant decrease in the cumulative 24-hour caloric intake in both obese and lean subjects. PYY infusion reduced plasma levels of the appetite-stimulatory hormone ghrelin. Endogenous fasting and postprandial levels of PYY were significantly lower in obese subjects (the mean [+/-SE] fasting PYY levels were 10.2+/-0.7 pmol per liter in the obese group and 16.9+/-0.8 pmol per liter in the lean group, P<0.001). Furthermore, the fasting PYY levels correlated negatively with the body-mass index (r = -0.84, P<0.001). CONCLUSIONS: We found that obese subjects were not resistant to the anorectic effects of PYY. Endogenous PYY levels were low in the obese subjects, suggesting that PYY deficiency may contribute to the pathogenesis of obesity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Studies with PYY agonists administered intravenously have shown reduction in food intake with increased satiety [92, 93], however, a nasal PYY agonist showed minimal efficacy with poor tolerability [94].”
From What is the pipeline for future medications for obesity? (2025) · cites this paper as [93]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“On the other hand, GLP-1 RA can reduce epicardial fat and semaglutide 2.4 mg have shown to improve physical function and symptoms in people with HFpEF [93].”
From What is the pipeline for future medications for obesity? (2025) · cites this paper as [93]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Central nervous system control of food intake
Schwartz, M. W., Woods, S. C., Porte, D., Seeley, R. J., & Baskin, D. G. (2000) · Nature · doi:10.1038/35007534 · Cited by 6,451 · cited 1×
“Gut hormone PYY(3-36) physiologically inhibits food intake.”
Ghrelin induces adiposity in rodents
Tschöp, M., Smiley, D. L., & Heiman, M. L. (2000) · Nature · doi:10.1038/35038090 · Cited by 3,949 · cited 1×
“Gut hormone PYY(3-36) physiologically inhibits food intake.”
The Eating Attitudes Test: an index of the symptoms of anorexia nervosa
Garner, D. M., & Garfinkel, P. E. (1979) · Psychological Medicine · doi:10.1017/s0033291700030762 · Cited by 3,543 · cited 1×
“Gut hormone PYY(3-36) physiologically inhibits food intake.”
A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans
Cummings, D. E., Purnell, J. Q., Frayo, R. S., Schmidova, K., Wisse, B. E., & Weigle, D. S. (2001) · Diabetes · doi:10.2337/diabetes.50.8.1714 · Cited by 2,940 · cited 1×
“Gut hormone PYY(3-36) physiologically inhibits food intake.”
Ghrelin enhances appetite and increases food intake in humans
Wren, A. M., Seal, L. J., Cohen, M. A., Brynes, A. E., Frost, G. S., Murphy, K. G., Dhillo, W. S., Ghatei, M. A., & Bloom, S. R. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.12.8111 · Cited by 2,494 · cited 1×
“Gut hormone PYY(3-36) physiologically inhibits food intake.”
Self-citationLeptin activates anorexigenic POMC neurons through a neural network in the arcuate nucleus
Cowley, M. A., Smart, J. L., Rubinstein, M., Cerdán, M. G., Diano, S., Horvath, T. L., Cone, R. D., & Low, M. J. (2001) · Nature · doi:10.1038/35078085 · Cited by 2,356 · cited 1×
“Gut hormone PYY(3-36) physiologically inhibits food intake.”
Gut hormone PYY3-36 physiologically inhibits food intake
Batterham, R. L., Cowley, M. A., Small, C. J., Herzog, H., Cohen, M. A., Dakin, C. L., Wren, A. M., Brynes, A. E., Low, M. J., Ghatei, M. A., et al. (2002) · Nature · doi:10.1038/nature00887 · Cited by 2,351 · cited 1×
“Gut hormone PYY(3-36) physiologically inhibits food intake.”
Self-citationPlasma Ghrelin Levels after Diet-Induced Weight Loss or Gastric Bypass Surgery
Cummings, D. E., Weigle, D. S., Frayo, R. S., Breen, P. A., Ma, M. K., Dellinger, E. P., & Purnell, J. Q. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012908 · Cited by 2,241 · cited 1×
“Gut hormone PYY(3-36) physiologically inhibits food intake.”
Glucagon-like peptide-1 7–36: a physiological incretin in man
Kreymann, B., Ghatei, M. A., Williams, G., & Bloom, S. R. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91194-9 · Cited by 1,928 · cited 1×
“Gut hormone PYY(3-36) physiologically inhibits food intake.”
Self-citationObesity in Adulthood and Its Consequences for Life Expectancy: A Life-Table Analysis
Peeters, A., Barendregt, J. J., Willekens, F., Mackenbach, J. P., Mamun, A. A., Bonneux, L., & and for NEDCOM, T. N. E. A. D. C. O. M. R. G. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-138-1-200301070-00008 · Cited by 1,479
Cited by
Items 701–800 of 1,003
Targeting the intestinal L-cell for obesity and type 2 diabetes treatment
Albrechtsen, N. J. W., Kuhre, R. E., Deacon, C. F., & Holst, J. J. (2013) · Expert Review of Endocrinology & Metabolism · doi:10.1586/17446651.2014.862152 · Cited by 34
Stefanidis, A., & Oldfield, B. J. (2017) · Journal of Neuroendocrinology · doi:10.1111/jne.12534 · Cited by 34
Gut hormones: the future of obesity treatment?
McGavigan, A. K., & Murphy, K. G. (2012) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2012.04278.x · Cited by 38
The regulation of circulating ghrelin — with recent updates from cell-based assays [Review]
Iwakura, H., Kangawa, K., & Nakao, K. (2014) · Endocrine Journal · doi:10.1507/endocrj.ej14-0419 · Cited by 40
“reported that PYY3-36 infusion to obese or lean subjects suppresses circulating ghrelin levels [204], whereas Ito et al.”
BackgroundGuida, C., McCulloch, L. J., Godazgar, M., Stephen, S. D., Baker, C., Basco, D., Dong, J., Chen, D., Clark, A., & Ramracheya, R. D. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13113 · Cited by 32
“For the acute experiments, islets were treated with sitagliptin (Stratech Scientific Ltd, Newmarket, UK), or with PYY (1-36) or PYY (3-36) (Bachem, Bubendorf, Switzerland) for 1 hour during glucose stimulation as described above.”
BackgroundMethodResultInfluentialDaousi, C., MacFarlane, I. A., English, P., Wilding, J. P. H., Patterson, M., Dovey, T. M., Halford, J. C. G., Ghatei, M. A., & Pinkney, J. H. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-1874 · Cited by 34
Self-citationIncreased Carbohydrate Induced Ghrelin Secretion in Obese vs. Normal‐weight Adolescent Girls
Misra, M., Tsai, P., Mendes, N., Miller, K. K., & Klibanski, A. (2009) · Obesity · doi:10.1038/oby.2009.86 · Cited by 37
“involved in the pathogenesis of obesity through decreased anorexigenic signals (3,8).”
BackgroundLampropoulos, C., Alexandrides, T., Tsochatzis, S., Kehagias, D., & Kehagias, I. (2021) · Obesity Surgery · doi:10.1007/s11695-021-05568-7 · Cited by 30
Fernández‐García, J. C., Murri, M., Coín‐Aragüez, L., Alcaide, J., Bekay, R. E., & Tinahones, F. J. (2013) · Clinical Endocrinology · doi:10.1111/cen.12221 · Cited by 34
Rohde, U., Federspiel, C. A., Vilmann, P., Langholz, E., Friis, S. U., Krakauer, M., Rehfeld, J. F., Holst, J. J., Vilsbøll, T., & Knop, F. K. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12800 · Cited by 30
“8) kg/m(2); glycated hemoglobin A1c (HbA1c), 32 [25-43] mmol/mol; fasting plasma glucose [FPG], 5.”
BackgroundThom, G., McIntosh, A., Messow, C., Leslie, W. S., Barnes, A. C., Brosnahan, N., McCombie, L., Malkova, D., Al-Mrabeh, A., Zhyzhneuskaya, S. V., et al. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14274 · Cited by 37
“Carbohydrate appears to be the most effective macronutrient in suppressing ghrelin due to postprandial insulin and glucose release, whereas fat has a weak effect,(44) and higher protein meals are more satiating and help to attenuate postprandial rises in ghrelin,(45) possibly mediated by increasing concentrations of s…”
BackgroundTyszkiewicz‐Nwafor, M., Jowik, K., Dutkiewicz, A., Krasińska, A., Pytlińska, N., Dmitrzak‐Węglarz, M., Sumińska, M., Pruciak, A., Skowrońska, B., & Słopień, A. (2021) · Nutrients · doi:10.3390/nu13020598 · Cited by 32
“PYY concentration increases shortly after a meal and stays elevated for several hours [17,18].”
BackgroundRecent progress in PYY research—An update report for 8th NPY meeting
Ashby, D. R., & Bloom, S. R. (2007) · Peptides · doi:10.1016/j.peptides.2006.10.019 · Cited by 38
Self-citationGastric stimulation for weight loss
Mizrahi, M., Yaʼacov, A. B., & Ilan, Y. (2012) · World Journal of Gastroenterology · doi:10.3748/wjg.v18.i19.2309 · Cited by 35
The global obesity epidemic: Snacking and obesity may start with free meals during infant feeding
Erlanson‐Albertsson, C., & Zetterström, R. H. (2005) · Acta Paediatrica · doi:10.1080/08035250500323780 · Cited by 33
“It inhibits food intake both in rodents and in humans [50].”
No Guts, No Loss: Toward the Ideal Treatment for Obesity in the Twenty-First Century
Hope, D. C. D., Tan, T., & Bloom, S. R. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00442 · Cited by 35
“Administration of PYY by infusion in human volunteers leads to reduced food intake and this effect is retained in patients with obesity (37, 38).”
BackgroundSelf-citationAn update on nutrition in chronic kidney disease
Fouque, D. P., & Guebre‐Egziabher, F. (2006) · International Urology and Nephrology · doi:10.1007/s11255-006-9108-3 · Cited by 37
The therapeutic potential of gut hormone peptide YY3-36 in the treatment of obesity
Small, C. J., & Bloom, S. R. (2005) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.14.5.647 · Cited by 31
“Recent work has identified the gut hormones PYY [13-15], oxyntomodulin [16] and pancreatic polypeptide (PP) [17] that inhibit appetite, and ghrelin [18,19], which stimulates appetite.”
BackgroundSelf-citationHanusch‐Enserer, U., & Roden, M. (2005) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2005.01514.x · Cited by 37
Review of Novel Aspects of the Regulation of Ghrelin Secretion
Al–Massadi, O., Lear, P., Müller, T. D., López, M., Diéguez, C., Tschöp, M. H., & Nogueiras, R. (2014) · Current Drug Metabolism · doi:10.2174/1389200215666140505153723 · Cited by 32
“This suggests that in humans PYY could be a therapeutic candidate in the treatment of obesity [109].”
BackgroundMilbank, E., Martínez, M. C., & Andriantsitohaina, R. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2015.11.002 · Cited by 33
“Interestingly, whereas circulating levels of PYY3-36 are lower in obese subjects, food intake is reduced in both obese and non-obese individuals after PYY3-36 administration, suggesting that PYY3-36 may be pharmaco-therapeutically interesting against obesity (Batterham et al., 2003).”
BackgroundHopkins, M., Beaulieu, K., Myers, A., Gibbons, C., & Blundell, J. E. (2017) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2017.1395693 · Cited by 36
“Peripheral administration of PYY 3-36 has been shown to decrease food intake in both rodents [53-55] and humans [56,57].”
Role of gastrointestinal hormones in feeding behavior and obesity treatment
Kairupan, T. S., Amitani, H., Cheng, K., Runtuwene, J., Asakawa, A., & Inui, A. (2015) · Journal of Gastroenterology · doi:10.1007/s00535-015-1118-4 · Cited by 41
“In human, intravenous infusion of PYY3-36 also showed the same results, indicating the role of PYY as an anorexigenic peptide [71].”
ResultObesity Pharmacotherapy: Current Perspectives and Future Directions
Misra, M. (2013) · Current Cardiology Reviews · doi:10.2174/157340313805076322 · Cited by 36
“In obese individuals, PYY3-36 intravenous infusion has been reported to ease hunger, decrease single-meal food intake by 30%, and significantly reduce the cumulative 24-hour caloric intake [130].”
BackgroundKanaley, J. A., Heden, T. D., Liu, Y., Whaley‐Connell, A. T., Chockalingam, A., Dellsperger, K. C., & Fairchild, T. J. (2013) · International Journal of Obesity · doi:10.1038/ijo.2013.84 · Cited by 32
“In both lean and obese subjects, infusion of PYY3-36 reduced food consumption (11-13), although there are conflicting results (14) suggesting that PYY infusion may need to be administered in a specific infusion pattern to exert its anorexigenic effects.”
The Role of Gut Hormones in Diet-Induced Weight Change: A Systematic Review
Zhao, X., Han, Q., Gang, X., Lv, Y., Liu, Y., Sun, C., & Wang, G. (2017) · Hormone and Metabolic Research · doi:10.1055/s-0043-115646 · Cited by 29
“Lower PYY levels was associated with increased appetite scores in fasting state [42, 44, 45], reflecting the physiological mechanism to sustain primary body weight.”
BackgroundHaluzík, M., Kratochvílová, H., Haluzíková, D., & Mráz, M. (2018) · Journal of Endocrinology · doi:10.1530/joe-17-0438 · Cited by 32
Cahill, F., Ji, Y., Wadden, D., Amini, P., Randell, E. W., Vasdev, S., Gulliver, W. P., & Sun, G. (2014) · PLoS ONE · doi:10.1371/journal.pone.0095235 · Cited by 32
“This group also proposed that endogenous PYY concentration was lower in obese rodents and humans, inversely associated with obesity-related phenotypes [13], and the administration of PYY could effectively reduce food intake and body weight independent of obesity status [1,13,14].”
BackgroundInfluentialFrom Bariatric to Pure Metabolic Surgery: New Concepts on the Rise
Santoro, S. (2014) · Annals of Surgery · doi:10.1097/sla.0000000000000590 · Cited by 30
Rosenkilde, M., Morville, T. H., Andersen, P. R., Kjær, K., Rasmusen, H. K., Holst, J. J., Dela, F., Westerterp, K. R., Sjödin, A. M., & Helge, J. W. (2015) · American Journal of Clinical Nutrition · doi:10.3945/ajcn.115.109918 · Cited by 30
“GLP-1, glucagon-like peptide 1; PYY3–36, polypeptide YY3–36; _VO2max, maximal oxygen uptake.”
BackgroundInfluentialLafferty, R. A., Gault, V. A., Flatt, P. R., & Irwin, N. (2019) · Clinical Medicine Insights Endocrinology and Diabetes · doi:10.1177/1179551419855626 · Cited by 28
“As such, PYY(1-36) is an established agonist for each subtype of the target neuropeptide Y receptor (NPYR) family, namely, NPYR1, NPYR2, NPYR4, and NPYR5,2 whereas PYY(3-36) is a highly selective NPYR2 agonist.”
BackgroundInfluentialRole of enteroendocrine hormones in appetite and glycemia
Ricardo-Silgado, M. L., MCRAE, A. N., & Acosta, A. J. (2021) · Obesity Medicine · doi:10.1016/j.obmed.2021.100332 · Cited by 32
Differences in gastrointestinal hormones and appetite ratings among obesity classes
Aukan, M. I., Nymo, S., Ollestad, K. H., Boyesen, G. A., DeBenedictis, J. N., Rehfeld, J. F., Coutinho, S. R., & Martins, C. (2022) · Appetite · doi:10.1016/j.appet.2022.105940 · Cited by 31
Althubeati, S., Avery, A., Tench, C. R., Lobo, D. N., Salter, A. M., & Eldeghaidy, S. (2022) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2022.104603 · Cited by 37
The influence of environmental temperature on appetite-related hormonal responses
Kojima, C., Sasaki, H., Tsuchiya, Y., & Goto, K. (2015) · Journal of PHYSIOLOGICAL ANTHROPOLOGY · doi:10.1186/s40101-015-0059-1 · Cited by 31
“Peptide YY (PYY) and glucagon-like peptide (GLP-1) play a role in attenuating appetite [2-5].”
BackgroundPeptide YY release in anorectic patients after liquid meal
Otto, B., Cuntz, U., Otto, C., Heldwein, W., Riepl, R. L., & Tschöp, M. H. (2006) · Appetite · doi:10.1016/j.appet.2006.06.008 · Cited by 28
Pancreatic polypeptide and peptide YY3–36 induce Ca2+ signaling in nodose ganglion neurons
Iwasaki, Y., Kakei, M., Nakabayashi, H., Ayush, E., Hirano-Kodaira, M., Maejima, Y., & Yada, T. (2012) · Neuropeptides · doi:10.1016/j.npep.2012.07.006 · Cited by 28
DeCarr, L. B., Buckholz, T. M., Milardo, L. F., Mays, M. R., Ortiz, A. A., & Lumb, K. J. (2007) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.01.045 · Cited by 28
New advances in models and strategies for developing anti-obesity drugs
Kim, G. W., Lin, J. E., Blomain, E. S., & Waldman, S. A. (2013) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2013.792804 · Cited by 37
“In studies conducted in healthy subjects, continuous infusion of PYY reduced hunger and caloric intake by 36% in a dose-dependent fashion [111,112], with a similar decrease seen in obese patients [105].”
BackgroundResultSiahanidou, T., Mandyla, H., Vounatsou, M., Anagnostakis, D., Papassotiriou, I., & Chrousos, G. P. (2005) · Clinical Chemistry · doi:10.1373/clinchem.2005.054908 · Cited by 28
“It has been reported that PYY administration caused a decrease in circulating ghrelin concentrations ( 36 ), but this was disputed in a later study (37).”
BackgroundHenry, K. E., Elfers, C., Burke, R. M., Chepurny, O. G., Holz, G. G., Blevins, J. E., Roth, C. L., & Doyle, R. P. (2015) · Endocrinology · doi:10.1210/en.2014-1825 · Cited by 28
Bone metabolism in anorexia nervosa and hypothalamic amenorrhea
Chou, S. H.-H., & Mantzoros, C. S. (2017) · Metabolism · doi:10.1016/j.metabol.2017.10.009 · Cited by 31
The association between FTO genotype with macronutrients and calorie intake in overweight adults
Mehrdad, M., Doaei, S., Gholamalizadeh, M., & Eftekhari, M. H. (2020) · Lipids in Health and Disease · doi:10.1186/s12944-020-01372-x · Cited by 32
“On the other hand, the FTO gene is related with gut hormones such as orexigenic hormone, acyl-ghrelin, satiety hormone, peptide YY that regulate food intake and appetite [40].”
BackgroundChandarana, K., & Batterham, R. L. (2008) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0b013e3282f3f4b1 · Cited by 32
Self-citationCatabolic effects of gastric bypass in a diet-induced obese rat model
Guijarro, A. I., Kirchner, H., & Meguid, M. M. (2006) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/01.mco.0000232903.04910.7b · Cited by 30
Investigational therapies in the treatment of obesity
Mancini, M. C., & Halpern, A. (2006) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.15.8.897 · Cited by 31
“The PYY infusion reduced hunger in both the obese and lean groups, and also decreased fasting concentrations of the orexigenic peptide ghrelin [90].”
BackgroundIto, T., ThidarMyint, H., Murata, T., Inoue, H., Neyra, R., & Kuwayama, H. (2006) · Journal of Endocrinology · doi:10.1677/joe.1.06855 · Cited by 28
“Batterham et al. (2003) reported that i.v. infusion of PYY3–36 to obese and lean subjects suppressed caloric intake and significantly decreased plasma total ghrelin levels, while Adams et al. (2004) reported that i.p. injection of PYY3–36 to overnight-fasted mice reduced feed intake significantly,…”
InfluentialNeuroendocrine Peptides of the Gut and Their Role in the Regulation of Food Intake
Schalla, M. A., Taché, Y., & Stengel, A. (2021) · Comprehensive physiology · doi:10.1002/cphy.c200007 · Cited by 30
Yuan, D., Zhou, C., Wang, T., Lin, F., Chen, H., Wu, H., Wei, R., Xin, Z., Liu, J., Gao, Y., et al. (2014) · Regulatory Peptides · doi:10.1016/j.regpep.2014.03.004 · Cited by 28
Eating disorders and gastrointestinal peptides
Tong, J., & D’Alessio, D. D. (2011) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0b013e328341e12b · Cited by 27
Balasubramaniam, A., Joshi, R., Su, C., Friend, L. A., & James, J. H. (2007) · Peptides · doi:10.1016/j.peptides.2006.08.041 · Cited by 27
Changes in physiology with increasing fat mass
Schuster, D. P. (2009) · Seminars in Pediatric Surgery · doi:10.1053/j.sempedsurg.2009.04.002 · Cited by 31
Gribble, F. M., Reimann, F., & Roberts, G. P. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-809954-4.00002-5 · Cited by 30
Viardot, A., Heilbronn, L. K., Herzog, H., Gregersen, S., & Campbell, L. V. (2008) · International Journal of Obesity · doi:10.1038/ijo.2008.24 · Cited by 27
Akkary, E., Sidani, S. M., Boonsiri, J., Yu, S., Dziura, J. D., Duffy, A. J., & Bell, R. L. (2008) · Surgical Endoscopy · doi:10.1007/s00464-008-0069-8 · Cited by 30
“PYY release is proportional to caloric intake [28] and has been shown to be reduced in obese subjects with resultant decreased satiety [29, 30].”
Peptide YY levels are associated with appetite suppression in response to long-chain fatty acids
Stoeckel, L. E., Weller, R. E., Giddings, M. J., & Cox, J. E. (2007) · Physiology & Behavior · doi:10.1016/j.physbeh.2007.08.018 · Cited by 27
Gastrointestinal surgery and gut hormones
Aylwin, S. (2005) · Current Opinion in Endocrinology & Diabetes · doi:10.1097/01.med.0000152979.05456.b6 · Cited by 28
Orr, J. S., & Davy, B. M. (2005) · Journal of the American Dietetic Association · doi:10.1016/j.jada.2005.04.005 · Cited by 33
The role of peptide YY in integrative gut physiology and potential role in obesity
Grudell, A., & Camilleri, M. (2007) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0b013e3280123119 · Cited by 28
National survey of pediatric fever management practices among emergency department nurses.
Thomas, V., Riegel, B. J., Andrea, J., Murray, P., Gerhart, A. E., & Gocka, I. (1994) · PubMed · Cited by 32
The gut sensor as regulator of body weight
Reinehr, T., & Roth, C. L. (2014) · Endocrine · doi:10.1007/s12020-014-0518-1 · Cited by 30
“Besides glucose, high-fat and protein-rich diets in particular can stimulate PYY release [29, 32, 33].”
InfluentialKokkinos, A. D., Tsilingiris, D., le Roux, C. W., Rubino, F., & Mantzoros, C. S. (2019) · Metabolism · doi:10.1016/j.metabol.2019.153960 · Cited by 29
Hughes, R., Horn, W. F., Wen, A., RUST, B. M., Woodhouse, L. R., Newman, J. W. I., & Keim, N. L. (2021) · Appetite · doi:10.1016/j.appet.2021.105802 · Cited by 27
Ukkola, O. H., Puurunen, V.-P., Piira, O.-P., Niva, J., Lepojärvi, E. S., Tulppo, M. P., & Huikuri, H. V. (2011) · Regulatory Peptides · doi:10.1016/j.regpep.2011.05.006 · Cited by 27
Paik, K. H., Jin, D., Lee, K. H., Armstrong, L., Lee, J. E., Oh, Y. J., Kim, S., Kwon, E. K., & Choe, Y. H. (2007) · Journal of Korean Medical Science · doi:10.3346/jkms.2007.22.3.436 · Cited by 26
“It has been reported that endogenous PYY levels are low in obese subjects, suggesting that PYY deficiency may contribute to the pathogenesis of obesity (18).”
BackgroundEffects of endurance running and dietary fat on circulating ghrelin and peptide YY.
Russel, R. R., Willis, K. S., Ravussin, É., & Larson‐Meyer, E. (2009) · Europe PMC (PubMed Central) · Cited by 26
Maher, T., Deleuse, M., Thondre, S., Shafat, A., & Clegg, M. (2020) · European Journal of Nutrition · doi:10.1007/s00394-020-02235-y · Cited by 27
Yan, W., Polidori, D., Yieh, L., Di, J., Wu, X., Moreno, V., Li, L., Briscoe, C. P., Shankley, N. P., Dohm, G. L., et al. (2014) · Obesity Surgery · doi:10.1007/s11695-014-1316-9 · Cited by 28
Effect of Glycemic Load on Peptide‐YY Levels in a Biracial Sample of Obese and Normal Weight Women
Brownley, K. A., Heymen, S., Hinderliter, A. L., & MacIntosh, B. (2009) · Obesity · doi:10.1038/oby.2009.368 · Cited by 28
“Peptide YY(3-36)-induced inhibition of food intake in female monkeys.”
BackgroundInfluentialMedical Therapy for Obesity—Current Status and Future Hopes
Bray, G. A. (2007) · Medical Clinics of North America · doi:10.1016/j.mcna.2007.06.013 · Cited by 27
Baskaran, C., Eddy, K. T., Miller, K. K., Meenaghan, E. M., Misra, M., & Lawson, E. A. (2016) · European Journal of Endocrinology · doi:10.1530/eje-15-0875 · Cited by 25
Holst, J. J., Jepsen, S. L., & Modvig, I. M. (2022) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2022.102189 · Cited by 29
Chichura, K. S., Elfers, C., Salameh, T. S., Kamat, V., Chepurny, O. G., McGivney, A., Milliken, B. T., Holz, G. G., Applebey, S. V., Hayes, M. R., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-36178-1 · Cited by 27
Xu, J., McNearney, T. A., & Chen, J. D. Z. (2010) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2010.06563.x · Cited by 25
Neuroendocrine regulation of food intake
Chaptini, L. A., & Peikin, S. R. (2008) · Current Opinion in Gastroenterology · doi:10.1097/mog.0b013e3282f3f4d8 · Cited by 26
den Hoed, M., Smeets, A. J. P. G., Veldhorst, M. A. B., Nieuwenhuizen, A. G., Bouwman, F. G., Heidema, A. G., Mariman, E. C. M., Westerterp‐Plantenga, M. S., & Westerterp, K. R. (2008) · International Journal of Obesity · doi:10.1038/ijo.2008.195 · Cited by 25
Khoury, D. T. D. E., Rassi, R. E., Azar, S. T., & Hwalla, N. C. (2010) · European Journal of Nutrition · doi:10.1007/s00394-010-0108-9 · Cited by 31
“PYY levels decrease following 2‐3 days of fasting [14], increase after meal ingestion and induce satiety when peripherally injected [ 15 ], suggesting a role for PYY in meal termination in humans.”
BackgroundBone health in eating disorders
Zuckerman‐Levin, N., Hochberg, Z., & Latzer, Y. (2013) · Obesity Reviews · doi:10.1111/obr.12117 · Cited by 30
“Ghrelin is an orexigenic gastric peptide hormone and promotes osteoblastic proliferation and differentiation in vitro (86).”
BackgroundGastrointestinal peptides in eating-related disorders
Smith, K., & Moran, T. H. (2021) · Physiology & Behavior · doi:10.1016/j.physbeh.2021.113456 · Cited by 28
An overview of neuropeptide Y: pharmacology to molecular biology and receptor localization
Dumont, Y., & Quirion, R. (2006) · Birkhäuser-Verlag eBooks · doi:10.1007/3-7643-7417-9_2 · Cited by 29
Fontán, M. P., Cordido, F., Rodríguez–Carmona, A., Penin, M., Cambre, H. D., Lopez-Muniz, A., Sangiao‐Alvarellos, S., & García‐Buela, J. (2008) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfn297 · Cited by 26
“Furthermore, baseline levels of PYY3–36 are lower in obese than in lean individuals, lending further support to the potential role for this peptide in the pathogenesis of obesity [18,33,34].”
BackgroundEndocrine response to fasting in the overwintering captive raccoon dog (Nyctereutes procyonoides)
Nieminen, P., Saarela, S. Y. O., Pyykönen, T., Asikainen, J., Mononen, J., & Mustonen, A. (2004) · Journal of Experimental Zoology Part A Comparative Experimental Biology · doi:10.1002/jez.a.126 · Cited by 28
Appetite and Body Weight Regulation
Vasselli, J. R. (2012) · Wiley eBooks · doi:10.1002/9781394323142.ch8 · Cited by 26
Association of Gut Hormones and Microbiota with Vascular Dysfunction in Obesity
Rovella, V., Rodia, G., Daniele, F. D., Cardillo, C., Campia, U., Noce, A., Candi, E., Della‐Morte, D., & Tesauro, M. (2021) · Nutrients · doi:10.3390/nu13020613 · Cited by 25
“PYY has anorectic effect [122], acting through the Neuropeptide Y receptors (NPYs) located on enterocytes, myenteric, and submucosal neurons, afferent fiber, and in CNS [166] (Figure 2).”
BackgroundWalker, E. G., Lo, K., Pahl, M. C., Shin, H. S., Lang, C., Wohlers, M. W., Poppitt, S. D., Sutton, K. H., & Ingram, J. R. (2022) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/nqab418 · Cited by 26
Medical treatment of weight loss in children and adolescents with obesity
Calcaterra, V., Rossi, V., Mari, A., Casini, F., Bergamaschi, F., Zuccotti, G., & Fabiano, V. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106471 · Cited by 26
Energy Homoeostasis: The Roles of Adipose Tissue-Derived Hormones, Peptide YY and Ghrelin
Hall, J., Roberts, R. E., & Vora, N. (2009) · Obesity Facts · doi:10.1159/000208517 · Cited by 29
Adult-onset PYY overexpression in mice reduces food intake and increases lipogenic capacity
Shi, Y., Hammerle, C. M., Lee, I.-C. J., Turner, N. A., Nguyen, A., Riepler, S. J., Lin, S., Sainsbury, A., Herzog, H., & Zhang, L. (2012) · Neuropeptides · doi:10.1016/j.npep.2012.04.001 · Cited by 26
“One of these hormones is peptide YY (PYY), which has been recognized as an important mediator of satiety and which may play a role in the aetiology of obesity and type-2 diabetes (Batterham et al., 2003, Roth et al., 2005, Boey et al., 2006a and le Roux et al., 2006).”
BackgroundGastrointestinal Symptoms and Diseases Related to Obesity: An Overview
Foxx–Orenstein, A. E. (2010) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2009.12.006 · Cited by 26
Hansen, C. F., Vassiliadis, E., Vrang, N., Sangild, P. T., Cummings, B. P., Havel, P. J., & Jelsing, J. (2014) · Regulatory Peptides · doi:10.1016/j.regpep.2014.01.002 · Cited by 26
“In addition to proglucagon, L-cells are also known to express peptide tyrosine tyrosine (PYY) which leads to a marked inhibition of food intake in rodents and man [16,17].”
BackgroundThe emerging role of the intestine in metabolic diseases
Bradley, W. D., Zwingelstein, C., & Rondinone, C. M. (2011) · Archives of Physiology and Biochemistry · doi:10.3109/13813455.2011.578651 · Cited by 30
“Indeed, intravenous and nasal administration of PYY(3-36) to humans reduces caloric intake (Batterham et al., 2003; Degen et al., 2005).”
BackgroundNeuropharmacology of human appetite expression
Halford, J. C. G., & Harrold, J. A. (2008) · Developmental Disabilities Research Reviews · doi:10.1002/ddrr.20 · Cited by 24
Steinert, R. E., Ullrich, S. S., Geary, N., Asarian, L., Bueter, M., Horowitz, M., & Feinle‐Bisset, C. (2017) · Physiological Reports · doi:10.14814/phy2.13492 · Cited by 28
“There is evidence that protein inhibits eating and appetite more than carbohydrate or fat in healthy-weight and obese individuals (Batterham et al. 2003; Brennan et al. 2012), a notion reflected also in the protein leverage hypothesis (Simpson and Raubenheimer 2005; Gietzen and Aja 2012).”
BackgroundCan prebiotics assist in the management of cognition and weight gain in schizophrenia?
Kao, A. C.-C., Burnet, P. W. J., & Lennox, B. (2018) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2018.05.027 · Cited by 24
Veedfald, S., Wu, T., Bound, M. J., Grivell, J., Hartmann, B., Rehfeld, J. F., Deacon, C. F., Horowitz, M., Holst, J. J., & Rayner, C. K. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-00699 · Cited by 24
Differential Secretion of Satiety Hormones With Progression of Obesity in JCR:LA‐corpulent Rats
Parnell, J. A., & Reimer, R. A. (2008) · Obesity · doi:10.1038/oby.2007.128 · Cited by 26
“PYY[3-36] administration decreases the respiratory quotient and reduces adiposity in diet-induced obese mice.”
BackgroundGhrelin in Chronic Kidney Disease: Too Much or Too Little?
MAK, R. H. K., Cheung, W., & Purnell, J. Q. (2007) · Peritoneal Dialysis International · doi:10.1177/089686080702700112 · Cited by 24
“These include total calories (13), carbohydrates (vs fats and protein) (14), insulin and insulin resistance (15), PYY3–36 (16), glucagon-like peptide-1 (17), vagal tone (18), somatostatin (19), and surgical changes in the intestinal anatomy (20,21).”
BackgroundWhited, K. L., Tso, P., & Raybould, H. E. (2007) · Endocrinology · doi:10.1210/en.2006-1665 · Cited by 24
Frezza, E. E. (2004) · Obesity Surgery · doi:10.1381/0960892041719699 · Cited by 24
Gastrointestinal Hormones and Neurotransmitters
Liddle, R. A. (2010) · Elsevier eBooks · doi:10.1016/b978-1-4160-6189-2.00001-9 · Cited by 25
Metadata
- Authors
- Batterham, R. L., Cohen, M. A., Ellis, S. M., Le Roux, C. W., Withers, D. J., Frost, G. S., Ghatei, M. A., & Bloom, S. R.
- Affiliations
- Imperial College London (GB)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2003-09-04
- Volume
- 349
- Issue
- 10
- Pages
- 941-948
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2170277935
- Cited by
- 1,604
- References
- 27
- Citations by year
- 2026: 31 · 2025: 28 · 2024: 31 · 2023: 29 · 2022: 33 · 2021: 54 · 2020: 40 · 2019: 63 · 2018: 44 · 2017: 61 · 2016: 61 · 2015: 60 · 2014: 78 · 2013: 83 · 2012: 89
- FWCI
- 38.12
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Topics
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuropeptides and Animal Physiology
- Keywords
- PYY3-36, peptide YY, obesity, dietary intake, appetite, ghrelin, leptin resistance, gastrointestinal hormones, hypothalamic regulation of appetite, body mass index, energy intake
- MeSH terms
- Appetite, Double-Blind Method, Eating, Female, Humans, Insulin, Male, Obesity, Peptide Fragments, Cross-Over Studies, Peptide YY, Leptin, Peptide Hormones, Ghrelin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.